Berry WR - Search Results

1

Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer.

Sonpavde G, Aparicio AM, Zhan F, North B, Delaune R, Garbo LE, Rousey SR, Weinstein RE, Xiao L, Boehm KA, Asmar L, Fleming MT, Galsky MD, Berry WR, Von Hoff DD. Sonpavde G, et al. Among authors: berry wr. Urol Oncol. 2011 Nov-Dec;29(6):682-9. doi: 10.1016/j.urolonc.2009.09.015. Epub 2009 Dec 3. Urol Oncol. 2011. PMID: 19959380 Clinical Trial.

2

Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer.

Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L. Berry W, et al. J Urol. 2002 Dec;168(6):2439-43. doi: 10.1016/S0022-5347(05)64163-8. J Urol. 2002. PMID: 12441935 Clinical Trial.

3

Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer.

Berry WR, Hathorn JW, Dakhil SR, Loesch DM, Jackson DV, Gregurich MA, Newcomb-Fernandez JK, Asmar L. Berry WR, et al. Clin Prostate Cancer. 2004 Sep;3(2):104-11. doi: 10.3816/cgc.2004.n.020. Clin Prostate Cancer. 2004. PMID: 15479494 Clinical Trial.

4

Hormone refractory prostate cancer: Management and advances.

Sonpavde G, Hutson TE, Berry WR. Sonpavde G, et al. Among authors: berry wr. Cancer Treat Rev. 2006 Apr;32(2):90-100. doi: 10.1016/j.ctrv.2005.12.005. Epub 2006 Feb 3. Cancer Treat Rev. 2006. PMID: 16458434 Review.

5

Systemic chemotherapy for urothelial cancer.

Sonpavde G, Hutson TE, Berry WR. Sonpavde G, et al. Among authors: berry wr. Clin Genitourin Cancer. 2006 Jun;5(1):34-42. doi: 10.3816/CGC.2006.n.015. Clin Genitourin Cancer. 2006. PMID: 16859577 Review.

6

Problems with the randomized discontinuation design.

Sonpavde G, Hutson TE, Galsky MD, Berry WR. Sonpavde G, et al. Among authors: berry wr. J Clin Oncol. 2006 Oct 1;24(28):4669-70; author reply 4670-1. doi: 10.1200/JCO.2006.08.1026. J Clin Oncol. 2006. PMID: 17008711 No abstract available.

7

A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer.

Berry W, Friedland D, Fleagle J, Jackson D, Ilegbodu D, Boehm KA, Asmar L. Berry W, et al. Clin Genitourin Cancer. 2006 Sep;5(2):131-7. doi: 10.3816/CGC.2006.n.029. Clin Genitourin Cancer. 2006. PMID: 17026801 Clinical Trial.

8

Phase II study of low-dose docetaxel/estramustine in elderly patients or patients aged 18-74 years with hormone-refractory prostate cancer.

Chittoor S, Berry W, Loesch D, Logie K, Fleagle J, Mull S, Boehm KA, Zhan F, Asmar L. Chittoor S, et al. Clin Genitourin Cancer. 2006 Dec;5(3):212-8. doi: 10.3816/CGC.2006.n.039. Clin Genitourin Cancer. 2006. PMID: 17239275 Clinical Trial.

9

Results of a phase II study of weekly paclitaxel plus carboplatin in advanced carcinoma of unknown primary origin: a reasonable regimen for the community-based clinic?

Berry W, Elkordy M, O'Rourke M, Khan M, Asmar L. Berry W, et al. Cancer Invest. 2007 Feb;25(1):27-31. doi: 10.1080/07357900601130656. Cancer Invest. 2007. PMID: 17364554 Clinical Trial.

10

Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer.

Sonpavde G, Chi KN, Powles T, Sweeney CJ, Hahn N, Hutson TE, Galsky MD, Berry WR, Kadmon D. Sonpavde G, et al. Among authors: berry wr. Cancer. 2007 Dec 15;110(12):2628-39. doi: 10.1002/cncr.23085. Cancer. 2007. PMID: 17941029 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

139 results

Search Page